<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00501137</url>
  </required_header>
  <id_info>
    <org_study_id>H07-00928</org_study_id>
    <nct_id>NCT00501137</nct_id>
  </id_info>
  <brief_title>A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine</brief_title>
  <acronym>BCGov-01</acronym>
  <official_title>A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Simon Dobson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective is to determine if antibody responses to HPV types 16 &amp; 18 are non-inferior
      after a 2-dose paediatric regimen as compared to a 3-dose adult regimen of Q-HPV vaccination,
      with responses measured at Month 7.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Human Papillomavirus (HPV) infection is a cause of cervical cancer. Immunogenicity, safety
      and efficacy in the prevention of persistent infection from HPV 16 and 18 has been proven
      using a 3-dose regimen in adolescent and adult females using the Quadrivalent Human
      Papillomavirus (Q-HPV) vaccine. The intensity of the immune response is inversely
      proportional to age. Immunogenicity in adolescents 9-15 years of age is 1.7 - 2 times greater
      than in 16-26 year old vaccine recipients. Paediatric dosing studies are necessary and
      prudent given limited provincial funding for new biologics acquisition and programme service
      delivery. A reduction from an adult 3-dose HPV vaccine regimen to a pediatric 2-dose regimen
      will result in increased compliance to the full vaccine series and in significant savings to
      the health care system both in the cost of biologics and of program delivery and
      administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Objective Part 1</measure>
    <time_frame>Measured after Month 7</time_frame>
    <description>To determine if antibody responses to HPV types 16 &amp; 18 are non-inferior after a 2-dose paediatric regimen as compared to a 3-dose adult regimen of Q-HPV vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Objective Part 2</measure>
    <time_frame>At 18, 24 and 36mths post dose 1</time_frame>
    <description>To compare the serum antibody responses to HPV 6, 11, 16 &amp; 18 at months 18, 24 and 36 in 2-dose adolescent arm, 3-dose adolescent arm and 3-dose adult arm of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Objective Part 2</measure>
    <time_frame>Measured at 36 mths</time_frame>
    <description>To evaluate the memory B cell and T helper cell mediated immune response to Q-HPV vaccine in the 2-dose adolescent, 3-dose adolescent and 3-dose adult arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Objective Part 1 &amp; 2 - Antibody responses 2 doses between 9-13 vs 16-26</measure>
    <time_frame>Measured at 7, 18,24 and 36 mths</time_frame>
    <description>To demonstrate that 2-doses of Q-HPV vaccine administered to 9-13 year old females produces a serum antibody response to HPV 6 and 11 that is similar to the response seen in 16-26 year olds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Objective Part 1 &amp; 2 - HPV 16 and 18 2 doses versus 3</measure>
    <time_frame>Measured at 7,18,24 and 36 mths</time_frame>
    <description>To evaluate the antibody responses to HPV 16 and 18 in 9-13 year old females after a 2-dose versus a 3-dose Q-HPV regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Objective Part 1 seroconversion rates</measure>
    <time_frame>Measured at 7 mths</time_frame>
    <description>To evaluate seroconversion rates to HPV 6, 11, 16, and 18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Objective Part 1 Memory Response</measure>
    <time_frame>Measured at 7 mths</time_frame>
    <description>To evaluate the memory B cell and T helper cell mediated immune response to Q-HPV vaccine in the 2-dose adolescent, 3-dose adolescent and 3-dose adult arms</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">830</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Genital Warts</condition>
  <arm_group>
    <arm_group_label>16-26 year olds 3 doses HPV Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 3 - 16-26 year olds receiving 3 doses HPV (Human Papillomavirus) Vaccine at 0, 2, 6 mths</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 dose 9-13 HPV Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 - 9-13 year olds receiving 3 doses HPV (Human Papillomavirus) Vaccine at 0,2,6 mths</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 dose 9-13 yrs HPV Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1 9-13 year olds 2 doses HPV (Human Papillomavirus) Vaccine at 0 and 6 mths</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HPV (Human Papillomavirus) Vaccine</intervention_name>
    <description>HPV (Human Papillomavirus) Vaccine received by all participants in groups 1, 2 and 3 according to the arm</description>
    <arm_group_label>16-26 year olds 3 doses HPV Vaccine</arm_group_label>
    <arm_group_label>3 dose 9-13 HPV Vaccine</arm_group_label>
    <arm_group_label>2 dose 9-13 yrs HPV Vaccine</arm_group_label>
    <other_name>Gardasil</other_name>
    <other_name>Q-HPV</other_name>
    <other_name>HPV Vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A female between, and including, 9-13 years (before 14th birthday) and 16-26 years of
             age (before 27th birthday) at the time of the first vaccination.

          -  Healthy

          -  Not pregnant

          -  Four or less sexual partners over lifetime as reported by subject. (Sexual activity is
             defined as intercourse)

          -  Not planning to become pregnant or likely to become pregnant

          -  No reported history of genital warts

          -  No laboratory confirmed history of cervical intraepithelial neoplasia

          -  No previous vaccination against HPV

          -  No administration of immunoglobulin and/or any blood products within the three months
             preceding the first dose of study vaccine or planned administration during the study
             period

          -  No previous anaphylactic reaction to HPV vaccine or any vaccine related component
             including aluminum hydroxyphosphate sulfate and polysorbate 80

          -  No confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history

          -  No bleeding diathesis or condition associated with prolonged bleeding time that would
             contraindicate intramuscular injection.

          -  Cannot be already enrolled in any clinical trial in which investigational vaccine or
             drug are being administered

        Exclusion Criteria

          -  Pregnant

          -  Female planning to become pregnant or likely to become pregnant (as determined by the
             investigator) during the study duration Part 1 (0-7 months)

          -  Reported history of genital warts

          -  Laboratory confirmed history of cervical intraepithelial neoplasia

          -  Greater than four lifetime sexual partners involving sexual intercourse

          -  Previous vaccination against HPV

          -  Administration of immunoglobulin and/or any blood products within the three months
             preceding the first dose of study vaccine or planned administration during the study
             period

          -  A previous anaphylactic reaction to HPV vaccine or any vaccine related component
             including aluminum hydroxyphosphate sulfate and polysorbate 80

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history (e.g. HIV infection, genetic defect, immunosuppressive therapy).
             *Chronic administration (defined as more than 14 days) of immune-modifying drugs
             within 6 months prior to the first vaccine dose or planned use during the study period
             is exclusionary (corticosteroid use - immune-modifying level is â‰¥0.5 mg/kg/day;
             inhaled or topical steroids are acceptable).

          -  Bleeding diathesis or condition associated with prolonged bleeding time that would
             contraindicate intramuscular injection (thrombocytopaenia, coagulation disorder,
             anti-coagulant therapy).

          -  Enrollment in any clinical trial in which investigational vaccine or drug are being
             administered
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Dobson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Scheifele, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vaccine Evaluation Centre, Vancouver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Meena Dawar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vaccine Evaluation Centre, Vancouver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tobias Kollman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vaccine Evaluation Centre, Vancouver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shelly McNeil, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre for Vaccinology, Halifax</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott Halperin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre for Vaccinology, Halifax</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joanne Langley, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre for Vaccinology, Halifax</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Dionne, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre de Recherche du CHUL (CHUQ), Quebec</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vaccine Evaluation Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.vec.med.ubc.ca</url>
    <description>click here for study details</description>
  </link>
  <results_reference>
    <citation>Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM, Bettinger JA, Singer J, Money D, Miller D, Naus M, Marra F, Young E. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013 May 1;309(17):1793-802. doi: 10.1001/jama.2013.1625.</citation>
    <PMID>23632723</PMID>
  </results_reference>
  <results_reference>
    <citation>Krajden M, Cook D, Yu A, Chow R, Su Q, Mei W, McNeil S, Money D, Dionne M, Palefsky J, Karunakaran K, Kollmann T, Ogilvie G, Petric M, Dobson S. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. Vaccine. 2014 Jan 23;32(5):624-30. doi: 10.1016/j.vaccine.2013.09.007. Epub 2013 Sep 19.</citation>
    <PMID>24055350</PMID>
  </results_reference>
  <results_reference>
    <citation>Krajden M, Cook D, Yu A, Chow R, Mei W, McNeil S, Money D, Dionne M, Karunakaran KP, Palefsky JM, Dobson S, Ogilvie G, Petric M. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol. 2011 Mar;18(3):418-23. doi: 10.1128/CVI.00489-10. Epub 2011 Jan 19.</citation>
    <PMID>21248158</PMID>
  </results_reference>
  <results_reference>
    <citation>Smolen KK, Gelinas L, Franzen L, Dobson S, Dawar M, Ogilvie G, Krajden M, Fortuno ES 3rd, Kollmann TR. Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine. 2012 May 21;30(24):3572-9. doi: 10.1016/j.vaccine.2012.03.051. Epub 2012 Mar 31.</citation>
    <PMID>22469863</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2007</study_first_submitted>
  <study_first_submitted_qc>July 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2007</study_first_posted>
  <last_update_submitted>April 8, 2015</last_update_submitted>
  <last_update_submitted_qc>April 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Simon Dobson</investigator_full_name>
    <investigator_title>Associate Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>HPV</keyword>
  <keyword>HPV vaccine</keyword>
  <keyword>Gardasil</keyword>
  <keyword>Human Papillomavirus</keyword>
  <keyword>vaccine</keyword>
  <keyword>2 dose versus 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

